Membrane Differences in Peripheral Blood Lymphocytes from Patients with Chronic Lymphocytic Leukemia and Hodgkin's Disease

Size: px
Start display at page:

Download "Membrane Differences in Peripheral Blood Lymphocytes from Patients with Chronic Lymphocytic Leukemia and Hodgkin's Disease"

Transcription

1 Proc. Nat. Acad. Sci. USA Vol. 72, No. 6, pp , June 1975 Membrane Differences in Peripheral Blood Lymphocytes from Patients with hronic Lymphocytic Leukemia and Hodgkin's Disease (concanavalin A/cell agglutination/cell attaclhment/cap formation) URI MINTZ AND LEO SAHS Department of Genetics, Weizmann Institute of Science, Rehovot, Israel; and Department of Oncology, Beilinson Medical enter, Tel-Aviv University Medical School, Israel ommunicated by George Klein, March 3, 1975 ABSTRAT Lymphocytes were isolated from the peripheral blood of 21 normal persons and 66 patients with patients with chronic lymphocytic leukemia (LL) with or peripheral blood lymphocytes of 21 normal persons, 2 chronic lymphocytic leukemia (LL), LL in remission, Hodgkin's disease, Hodgkin's disease in remission, various without treatment, 15 patients with untreated Hodgkin's other tumors, or cardiovascular diseases. The lymphocytes disease, 12 patients with various other tumors, and 1 patients were studied for cap formation and agglutinability by with nonmalignant diseases (cardiovascular diseases). In order concanavalin A, and for cell attachment to the surface of a to determine to what extent patients in clinical remission may petri dish. The frequency of cap formation was lowest in lymphocytes from patients with untreated Hodgkin's disease (2.1 ±.8%), next lowest in lymphocytes from pa- seen in patients with active disease, we have also included six still show surface membrane changes if lymphocytes like those tients with LL who were or were not under treatment patients with Hodgkin's disease in remission and three patients with LL in remission. ( %), and also low in Hodgkin's disease in remission ( %). The frequencies of cap formation by lymphocytes from patients with various other tumors MATERIALS AND METHODS (19.1 ± 2.5%), with LL in remission (24. ±.9%), and with nonmalignant diseases ( %) were more ells. Peripheral blood samples from healthy adult donors similar to the frequency found in lymphocytes from normal persons ( %). Lymphocytes from all the containing 1 units/ml of heparin. All experiments were car- and the different patients were collected into sterile syringes patients, including those in remission, showed a higher degree of agglutinability by concanavalin A than lymphocytes from normal persons. ell attachment to a petri isolated by Ficoll-Hypaque gradient centrifugation (6) and ried out with freshly isolated cells. The lymphocytes were dish was highest with LL, next highest with LL in remission, and low for normal persons and all the other the interphase that contains the lymphocytes were washed the gradients centrifuged for 3 min at 4 X g. ells from patients. Lymphocytes from normal persons that consisted predominantly of thymus-derived cells gave similar three times with phosphate-buffered saline at ph 7.2 and results to isolated normal bone marrow-derived cells. diluted in the same buffer for the experiments. In some experiments, the cells isolated from the gradient were suspended The results indicate that there were different changes in the surface membrane of lymphocytes from patients with in a solution containing iron filings (Technicon Products, New LL, LL in remission, Hodgkin's disease, and Hodgkin's York), incubated for 3 mill at 24 on a lay-adams electrical disease in remission, and that the patients in clinical remission still showed abnormalities in their lymphocytes. rotor at 6 rpm, and the cells with iron filings removed with a magnet. Experiments with two normal persons, two patients The analysis of differences in the surface membrane of normal with LL, and two patients with Hodgkin's disease showed a and malignant cells can be of value in elucidating the mechanism of carcinogenesis and leukemogenesis. Among the mem- induced cap formation, and a slightly lower degree of on A- similar degree of cell attachment and frequency of on A- brane changes that can be analyzed are the interaction of cells induced agglutination, after removal of the cells with iron with various lectins (1, 2) and the ability of cells to attach filings. Bone marrow-derived cells (B cells) from normal to the surface of a petri dish (3, 4). Studies with the lectin persons were separated by using the capacity of thymusderived cells (T cells) to form rosettes with sheep erythrocytes concanavalin A (on A) have shown differences in on A- induced cap formation and agglutinability between normal (7-1). lymphocytes and lymphocytic leukemic cells from mice (1, 2). Experiments on cap formation, agglutinability, and the Patients and Normal Persons. The 2 patients with LL, degree of cell attachment to the surface of a petri dish have also indicated that these are useful criteria for determining changes who had been diagnosed 2 months to 16 years previously, were nine women and 11 men, years old, with leukocyte counts in the surface membrane of human peripheral blood lymphocytes from patients with lymphoproliferative disease (4, 5). of 18,-14, cells/mm3 of which 6-96% were lymphocytes. Seventeen of these patients had received no The present experiments were undertaken to use these treatment for at least 2 years, and the other three were under criteria to detect differences in the surface membranes of daily treatment for 1-2 months with 2-3 mg of prednisone and 2 mg of chlorambucil. The three patients with LL in remission had been diagnosed 5-12 years previously as Abbreviations: LL, chronic lymphocytic leukemia; concanavalin A on A,; F-on A, fluorescein isothiocyanate conju- LL, had been in remission for 4-6 years, and had not been having gated with concanavalin A; B cells, bone marrow-derived cells; under treatment for at least 2 years. They were two women 7T cells, thymus-derived cells. and one man, 6-66 years old, with leukocyte counts of

2 Proc. Nat. Acad. Sci. USA 72 (1975) 83 cells/mm3 of which 24-45% were lymphocytes. Before these patients were in remission, two had not been treated and the third had been treated daily for 1 and 2 months with 1 mg of prednisone and 2 mg of chlorambucil before remission. The 15 patients with Hodgkin's disease were six women and nine men, years old, in stages IIB, IIIA, IHIB, and IVB. The diagnoses were all made after staging laparotomy and the histological patterns were lymphocyte predominance, nodular sclerosis, mixed cellularity, or lymphocyte depletion. All were newly diagnosed patients who had not been treated and who had leukocyte counts of 5,7-23, cells/mm3 of which 3-29% were lymphocytes. The six patients with Hodgkin's disease in remission had been diagnosed as having Hodgkin's disease 15 months to 1.5 years previously and had been in remission for 7 months to 1 years, during which time they had not been under treatment. They were one woman and five men, years old, with leukocyte counts of 4,8-1,4 cells/mm3 of which 26-32% were lymphocytes. Before these patients were in remission, five had been treated with irradiation and one with combination chemotherapy. Of the 12 patients with various malignant tumors, two had carcinoma of the cervix uteri, two had breast carcinoma, two had carcinoma of the lung, one patient each had carcinoma of the stomach, ovary, or endometrium, and one patient each had malignant lymphoma, malignant melanoma, or multiple myeloma. rhese patients were seven women and five men, years old, with leukocyte counts of 5,1-16,5 cells/ mm3 of which 7-39% were lymphocytes. The patients with carcinoma of the stomach, ovary, or endometrium, and with malignant lymphoma had been newly diagnosed after total gastrectomy or hysterectomy in the patients with carcinomas and had not received any chemotherapy or irradiation. The two patients with carcinoma of the breast had been diagnosed 6 years earlier and had received no chemotherapy for 2 months or 1 year. Of the two patients with lung carcinoma, one had been diagnosed 2 months earlier and was receiving daily local irradiation for 5 days a week and the other, diagnosed 16 months earlier, had not been irradiated for the previous 7 months. The two patients with carcinoma of the cervix uteri had been diagnosed 2-3 months previously and were receiving daily local irradiation. The patients with multiple myeloma and malignant melanoma were diagnosed 2 and 14 months previously and were being treated with alkeran or BG (Bacillus almette Guerin), respectively. The 1 patients with nonmalignant diseases were five women and five men, 5-71 years old, with atherosclerotic heart disease, coronary insufficiency, rheumatic heart disease, hypertension, or cerebrovascular accident. All except one were under treatment for at least 6 months with digoxin, propranolol, or methyl-dopa. The leukocyte counts were 5,-9,4 cells/mm3 of which 12-35% were lymphocytes. The 66 patients in the present study include 15 patients with LL, 1 with Hodgkin's disease, and three with LL in remission, used in a previous study (4). The 21 normal persons were three women and 18 men, years old, with leukocyte counts of 4,7-1,2/mm3 of which 27-35% were lymphocytes. on A-Induced ap Formation and Agglutination. Fluorescein isothiosyanate conjugated with on A (F-on A) was obtained from Miles-Yeda, Rehovot. The cells were tested Leukemia and Hodgkin's Disease 2429 for cap formation by incubating with F-on A (1 iug/ml) for 15 min at 37, washing with phosphate-buffered saline, pipetting to dissociate aggregates, and counting the number of cells with a cap in a Zeiss fluorescent microscope. Four hundred cells were counted for each determination and only single cells were counted for calculating the percentage of cells with caps. Similar results were obtained with 1 jtg of F-on A per ml. ells were also incubated with vinblastine sulfate (Eli Lilly and o.) for 3 min at 37 before incubation with F-on A. To test for agglutination, we mixed.5 ml of on A diluted in phosphate-buffered saline to different concentrations with.5 ml of a cell suspension in a 35 mm petri dish (Falcon Plastics no. 18) at a final concentration of 5 X 16 cells per ml. The density and size of aggregates were scored in a scale from - to after a 3 min incubation and shaking at 24 on a lay-adams electrical rotator at 6 rpm. ell Attachment to the Surface of a Petri Dish. ell suspensions (prepared in the same way as for the agglutination assay) of 5 X 16 cells per ml were incubated in 35 mm petri dishes (Falcon Plastics no. 18) for 3 min at 24 with a slight shaking by hand for the first 5 min and then about every 5 min. The amount of cell attachment to the surface of the petri dish was scored in a scale from - to In this scale, ++++ indicated that more than about 75% of the cells were attached (4). No obvious differences were observed between scoring after a light washing of the attached cells with phosphate-buffered saline and scoring without washing so that the results were generally scored without washing. Two to four petri dishes were used for each determination. RESULTS on A-induced cap formation The isolated peripheral blood lymphocytes from 21 normal and 66 patients were tested for on A-induced cap formation. Among these patients were 2 with LL and 15 with Hodgkin's disease. The percentage of T cells in peripheral blood lymphocytes is about 5-8% for normal persons, generally less than 1% for patients with LL, and about 5-7% for patients with Hodgkin's disease (11, 12). A on A-induced cap was seen in 24-36% of the lymphocytes from normal donors which were predominantly T cells and a similar percentage (about 3%) was seen in isolated normal B cells. However, 5-9% of the lymphocytes from LL patients had a cap and only 1-3% of lymphocytes from patients with Hodgkin's disease had a cap (Fig. 1). The 15 patients with Hodgkin's disease had received no treatment. Seventeen of the 2 patients with LL had received no treatment for at least 2 years and three had been under daily treatment for 1-2 months with prednisone and chlorambucil. A similar percentage (5-9%) of cells with a cap was seen with LL patients who were or were not under treatment. ap formation was also tested in lymphocytes from six patients with Hodgkin's disease in remission, three with LL in remission, 12 with various tumors, and 1 with nonmalignant diseases. The various tumors included carcinomas, a multiple myeloma, a malignant melanoma, and a lymphoma. The nonmalignant diseases were cardiovascular diseases. Although 22-24% of the lymphocytes from the patients with LL in remission had a cap, a frequency similar to that found with some normal persons, only 9-13% of lymphocytes from

3 243 Medical Sciences: Mintz and Sachs Proc. Nat. Acad. Sci. USA 72 (1975) 4F-. x 3k " oo 4 a - *9 % * S*. ~~~~~~~ 4) L-) 2k 9 1o. el *. *. Hodgkin's disease Hodgkin's disease in remission LL LL in Various Non-malignant Normal remission tumors diseases FIG. 1. ap formation with fluorescent on A by lymphocytes from normal persons and different types of patients. ells were incubated with fluorescent on A and the percentage of single cells with a cap is shown for each patient and normal person. patients with Hodgkin's disease in remission had a cap. Of the lymphocytes from patients with various tumors and nonmalignant diseases, 16-24% and 24-32% had a cap, respectively (Fig. 1). Peripheral blood lymphocytes from all the normal persons and patients were also incubated with 1, 1, or 1 Mg/ml of vinblastine before incubation with F-on A. Treatment with vinblastine resulted, as in other experiments (4), in about a 1.5- to 2-fold increase in the percentage of cells with a cap and there was a maximum increase at 1 /Ag of vinblastine per ml. This increase by vinblastine did not eliminate the differences in the percentage of cap formation by lymphocytes from patients with LL, Hodgkin's disease, and Hodgkin's disease in remission (Table 1). on A-induced cell agglutination Agglutination with 5-25 &g of on A per ml shows that lymphocytes from all the patients were more highly agglutinable than the lymphocytes from normal persons (Fig. 2). The highest agglutinability was found for patients with LL, Hodgkin's disease, LL in remission, and Hodgkin's disease in remission. Despite the similarity in cap formation by cells from normal persons and from patients with LL in remission, the lymphocytes from patients with LL in remission showed the same high agglutinability as lymphocytes from patients with LL, Hodgkin's disease, and Hodgkin's disease in remission (Fig. 2). ell attachment to the surface of a petri dish Attachment of cells to a petri dish was measured after a 3 min incubation without or with different concentrations of on A (Fig. 3). The results without on A showed a high cell attachment by lymphocytes from patients with LL, an intermediate degree when LL was in remission and a low degree of attachment with lymphocytes from normal persons and all the other patients. The degree of cell attachment was increased by incubation with on A. However, even in the presence of on A, there was still the highest degree of attach- TABLE 1. on A-induced cap formation and agglutinability as well as cell attachment to the surface of a petri dish by lymphocytes from 21 normal persons and 66 patients No. of % ells with capt Agglutination with normal persons With vinblastine on A ell attachment Lymphocytes from* or patients Without vinblastine (1 jsg/ml) (25,g/ml) without on A Normal persons ± It 3.6 +to Nonmalignant diseases to Various tumors ± ± to LL 2 7. it ± LL in remission ±t ± Hodgkin's disease ± ± Hodgkin's disease in remission ±t * The nonmalignant diseases were cardiovascular diseases; the various tumors were carcinomas, a multiple myeloma, malignant melanoma, and lymphoma; LL = chronic lymphocytic leukemia. t Mean ± standard deviation.

4 Proc. Nat. Acad. Sci. USA 72 (1975) Leukemia and Hodgkin's Disease / E Hodgkin's disease / Hodgkin's in remission Various tumors Non-malignant diseases )/ o oncentration of on A(Qg/mt) FIG. 2. Lymphocyte agglutinability with different concentrations of on A. ment with LL and the next highest with LL in remission (Fig. 3). Isolated B lymphocytes from normal persons showed the same low degree of cell attachment and on A agglutinability, as do normal peripheral blood lymphocytes that consist mainly of T cells. DISUSSION The study of peripheral blood lymphocytes from the 21 normal persons and 66 patients with various diseases has shown that the three criteria used (percentage of cells with a on A- induced cap, agglutinability by on A, and cell attachment to the surface of a petri dish) can distinguish peripheral blood lymphocytes from patients with LL with and without treatment as well as from patients with untreated Hodgkin's disease, from lymphocytes from patients with various other tumors, cardiovascular diseases, and T and B lymphocytes from normal persons. The lymphocytes from patients with LL and Hodgkin's disease in clinical remission could also be distinguished from lymphocytes from normal persons (Table 1). The 12 patients with various other tumors included carcinomas, a multiple myeloma, malignant melanoma, and a lymphoma. The average percentage of cells with a cap (19.1 i 2.5%) was lower than that found with cardiovascular diseases (26. i 2.2%) or normal persons (29.4 i 3.8%). Further studies should determine to what extent this somewhat lower degree of cap formation is characteristic of certain types of tumors and the relationship between the different membrane changes and cellular lipids (1, 2, 13, 14). It will also be of interest to study patients with other types of nonmalignant diseases and to determine the possible modifying role of virus infection and serum factors on the membrane changes observed in peripheral blood lymphocytes. The lowest frequency of cap formation was found in Hodgkin's disease, 2.1 i.8% of lymphocytes from patients with Hodgkin's disease had a cap. This may account for the defect in delayed hypersensitivity that has been reported for patients with this disease (15). The presence of some lympho oncentration of on A(Mg/ml) FIG. 3. Attachment of lymphocytes to the surface of a petri dish without or with on A. The lymphocytes were scored for cell attachment after a 3 min incubation at 24. cytes with a cap may be either because some of the abnormal cells had retained the ability to form caps and/or the peripheral blood was contaminated with normal lymphocytes. Treatment of cells with vinblastine can increase the frequency of cap formation with normal lymphocytes (16). The differences in the percentage of lymphocytes with a cap in Hodgkin's disease, Hodgkin's disease in remission, LL, and normal persons, were not abolished by treating the cells with vinblastine. ap formation and agglutination by on A measure different types of mobility of surface receptors for this lectin. ap formation requires large lateral movements of receptors, whereas agglutination requires short-range lateral movements that allow the alignment of receptors for the formation of multiple bridges between cells by on A molecules (17, 18). Lymphocytes from normal persons and patients with LL in remission showed a similar percentage of cells with a cap but a difference in agglutinability. This indicates that these two criteria can help to distinguish lymphocytes which differ in one but not the other type of mobility. It will be of interest to compare the differences in mobility of on A receptors with differences in the mobility of surface antigens (19). The degree of cell attachment to the surface of a petri dish appears to measure a different change in the cell surface. Lymphocytes from patients with LL and Hodgkin's disease both differed from lymphocytes from normal persons, in their greater agglutinability and low frequency of cap formation. However, more lymphocytes from patients with LL attached to the surface of petri dishes than did those from Hodgkin's disease and all the other patients. Our results indicate that the changes in the surface membrane of peripheral blood lymphocytes from LL patients with or without treatment, untreated Hodgkin's disease, LL in remission, and Hodgkin's disease in remission were different

5 2432 Medical Sciences: Mintz and Sachs and that these changes were not found in lymphocytes from patients with various tumors and nonmalignant cardiovascular diseases. The results also indicate that the patients with LL and Hodgkin's disease in clinical remission still showed some abnormalities in their peripheral blood lymphocytes. Note Added in Proof. We have now found that the peripheral blood lymphocytes from seven patients with acute infectious mononucleosis had 4. i.7% cells with a on-a induced cap, a high degree of on A agglutinability, and an intermediate degree of cell attachment. Unlike the lymphocytes from normal persons or any of the other patients studied, the lymphocytes from infectious mononucleosis also showed a high degree of cell aggregation without on A. The changes in the surface membrane of peripheral blood lymphocytes from infectious mononucleosis were, therefore, different from tihe changes found with the other patients. 1. Sachs, L. (1974) in Harvey Lectures (Academic Press, New York), Vol. 68, pp Sachs, L. (1974) in ell Surface in Development, ed. Moscona, A. A. (Wiley Interscience, New York), pp Proc. Nat. Acad. Sci. USA 72 (1976) 3. Fibach, E. & Sachs, L. (1974) J. ell. Physiol. 83, Mintz, U. & Sachs, L. (1975.) Int. J. ancer 15, Ben-Bassat, H., Goldblum, N., Manny, N. & Sachs, L. (1974) Int. J. ancer 14, Boyum, A. (1968) Scand. J. lin. Lab. Invest. 21, Suppl Lay, W. H., Mendes, N. F., Bianco,. & Nussenzweig, V. (1971) Nature 23, Wybran, J., arr, M.. & Fudenberg, H. H. (1972) J. lin. Invest. 51, Froland, S. S. (1972) Scand. J. Immunol. 1, Polliack, A., Lampen, N., larkson, B. D., De Harven, E., Bentwich, Z., Siegal, F. & Kunkel, H. G. (1973) J. Exp. Med. 138, Seligman, M., Preud'homme, J. L. & Brouet, J.. (1973) Transplant. Rea. 16, ohnen, G., Augener, W., Buka, A. & Brittinger, G. (1974) Acta Haematol. 51, Gottfried, E. L. (1967) J. Lipid Res. 8, Vlodavsky, I. & Sachs, L. (1974) Nature 25, Eltringham, J. R. & Kaplan, H. S. (1973) Nat. ancer Inst. Monogr. 35, Edelman, G. M., Yahara, I. & Wang, J. L. (1973) Proc. Nat. Acad. Sci. USA 7, Rutishauser, U. & Sachs, L. (1974) Proc. Nat. Acad. Sci. USA 71, Rutishauser, U. & Sachs, L. (1975) J. ell Biol., in press. 19. Yefenof, E. & Klein, G. (1974) Exp. ell Res. 88,

I lymphocytes from patients with untreated

I lymphocytes from patients with untreated T AND B-RFC INHIBITING FACTOR IN PLASMA FROM PATIENTS WITH ACTIVE HODGKIN'S DISEASE EDIZ Z. EZDINLI, MD,* KATHI L. SIMONSON, BS,? LLOYD G. SIMONSON, PHD,$ AND LARRY P. WASSER, MD$ We report the presence

More information

BY Z. BENTWICH,~ S. D. DOUGLAS, E. SKUTELSKV, and H. G. KUNKEL

BY Z. BENTWICH,~ S. D. DOUGLAS, E. SKUTELSKV, and H. G. KUNKEL SHEEP RED CELL BINDING TO HUMAN LYMPHOCYTES TREATED WITH NEURAMINIDASE; ENHANCEMENT OF T CELL BINDING AND IDENTIFICATION OF A SUBPOPULATION OF B CELLS* BY Z. BENTWICH,~ S. D. DOUGLAS, E. SKUTELSKV, and

More information

IN VITRO CELLULAR RESPONSES TO AUTOLOGOUS TUMOR EXTRACT DETECTED BY INHIBITION OF MACROPHAGE MIGRATION*1

IN VITRO CELLULAR RESPONSES TO AUTOLOGOUS TUMOR EXTRACT DETECTED BY INHIBITION OF MACROPHAGE MIGRATION*1 [Gann, 66, 167-174; April, 1975] IN VITRO CELLULAR RESPONSES TO AUTOLOGOUS TUMOR EXTRACT DETECTED BY INHIBITION OF MACROPHAGE MIGRATION*1 Tsuyoshi AKIYOSHI, Akira HATA, and Hideo TSUJI Department of Surgery,

More information

Associated Antigens (membrane immunoflui

Associated Antigens (membrane immunoflui Proc. Nat. Acad. Sci. USA Vol. 72, No. 5, pp. 1671-1675, May 1975 Augmentation of Lymphocyte Cytotoxicity by Antibody to Herpesvirus saimiri Associated Antigens (membrane immunoflui e/lymphoma/disease

More information

however, and the present communication is concerned with some of

however, and the present communication is concerned with some of THE AGGLUTINATION OF HUMAN ERYTHROCYTES MODIFIED BY TREATMENT WITH NEWCASTLE DISEASE AND INFLUENZA VIRUS' ALFRED L. FLORMAN' Pediatric Service and Division of Bacteriology, The Mount Sinai Hospital, New

More information

~sal-equivalent or bone marrow-derived (B) lymphocytes;

~sal-equivalent or bone marrow-derived (B) lymphocytes; Human Lymphocyte Subpopulations EFFECT OF CORTICOSTEROIDS DAvD T. Y. Yu, PEEup J. CLEMENTS, HAROLD E. PAULUS, JAMES B. PETER, JOSHUA LEvy, and EUGENE V. BARNETr From the Department of Medicine, Division

More information

Ultrastructural Study of Human Natural Killer CNK) Cell*)

Ultrastructural Study of Human Natural Killer CNK) Cell*) Hiroshima Journal of Medical Sciences Vol. 31, No. 1, March, 1982 HJIM 31-6 31 Ultrastructural Study of Human Natural Killer CNK) Cell*) Yoshinori KAWAGUCHI, Eishi KITTAKA, Yoshito TANAKA, Takeo TANAKA

More information

Antibody-Dependent Cellular Cytotoxicity Against Influenza

Antibody-Dependent Cellular Cytotoxicity Against Influenza INFECTION AND IMMUNITY, OCt. 1983, p. 214-218 Vol. 42, No. 1 19-9567/83/1214-5$2./ Copyright 1983, American Society for Microbiology Ability of Human Cord Blood Lymphocytes to Mediate Antibody-Dependent

More information

IMMUNOLOGIC REACTIVITY IN HUMAN BREAST CANCER AGAINST CULTURED HUMAN BREAST TUMOR CELLS

IMMUNOLOGIC REACTIVITY IN HUMAN BREAST CANCER AGAINST CULTURED HUMAN BREAST TUMOR CELLS 22 IMMUNOLOGIC REACTIVITY IN HUMAN BREAST CANCER AGAINST CULTURED HUMAN BREAST TUMOR CELLS Michael P. Lerner*, J. H. Anglin, Peggy L. Munson, Peggy J. Riggs, Nancy E. Manning, and Robert E. Nordquist Departments

More information

Melanoma Bridge Meeting

Melanoma Bridge Meeting Melanoma Bridge Meeting Improving Adoptive Immune Therapy with Genetically Engineered T cells David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH 3 December 2015 Adoptive T Cell Therapy: Dose

More information

ab CytoPainter Golgi/ER Staining Kit

ab CytoPainter Golgi/ER Staining Kit ab139485 CytoPainter Golgi/ER Staining Kit Instructions for Use Designed to detect Golgi bodies and endoplasmic reticulum by microscopy This product is for research use only and is not intended for diagnostic

More information

Brief Definitive Report

Brief Definitive Report Brief Definitive Report HEMAGGLUTININ-SPECIFIC CYTOTOXIC T-CELL RESPONSE DURING INFLUENZA INFECTION BY FRANCIS A. ENNIS, W. JOHN MARTIN, ANY MARTHA W. VERBONITZ (From the Department of Health, Education

More information

10/18/2012. A primer in HLA: The who, what, how and why. What?

10/18/2012. A primer in HLA: The who, what, how and why. What? A primer in HLA: The who, what, how and why What? 1 First recognized in mice during 1930 s and 1940 s. Mouse (murine) experiments with tumors Independent observations were made in humans with leukoagglutinating

More information

Study of the One-Step Growth Curve of Equine Infectious Anemia Virus by Immunofluorescence

Study of the One-Step Growth Curve of Equine Infectious Anemia Virus by Immunofluorescence INFECTION AND IMMUNITY, June 1972, p. 89-895 Copyright 1972 American Society for Microbiology Vol. 5, No. 6 Printed in U.S.A Study of the One-Step Growth Curve of Equine Infectious Anemia Virus by Immunofluorescence

More information

Differentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia"

Differentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia Differentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia" Hoelzer, D.,l, Harriss, E. B.l, Kurrle, E.l, Schmücker, H.l, Hellriegel,

More information

MEDICAL DEFINITIONS REFERENCE GUIDES

MEDICAL DEFINITIONS REFERENCE GUIDES MEDICAL DEFINITIONS REFERENCE GUIDES What do the reference guides do? The reference guides provide updated definitions for certain claimable medical conditions under the following policies: St Andrew s

More information

Cell receptor studies on seven cases of diffuse

Cell receptor studies on seven cases of diffuse Cell receptor studies on seven cases of diffuse histiocytic malignant lymphoma (reticulum cell sarcoma) J. A. HABESHAW AND A. E. STUART From the Department ofpathology, University Medical School, Edinburgh

More information

ulation of NK cells that retain the capability of expressing the HNK-1 differentiation antigen. Children with the Chediak-Higashi (CH)' syndrome,

ulation of NK cells that retain the capability of expressing the HNK-1 differentiation antigen. Children with the Chediak-Higashi (CH)' syndrome, RAPID PUBLICATIONS Natural Killer (HNK-1l) Cells in Chediak-Higashi Patients Are Present in Numbers but Are Abnormal in Function and Morphology TORu ABO, JOHN C. RODER, WATARU ABO, MAX D. COOPER, and CHARLES

More information

Manipulation of T Cells in the Thnsplant Inoculum

Manipulation of T Cells in the Thnsplant Inoculum International Journal of Cell Cloning 4: 122-126 Suppl 1 (1986) Manipulation of T Cells in the Thnsplant Inoculum J. Kersey Bone Marrow Transplantation Program, University of Minnesota, Minneapolis, MN,

More information

TRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells

TRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells Journal of Supramolecular Structure 4:441 (401)-447 (407) (1976) TRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells

More information

AUTOIMMUNE RESPONSES TO HUMAN TUMOUR ANTIGENS

AUTOIMMUNE RESPONSES TO HUMAN TUMOUR ANTIGENS 510 AUTOIMMUNE RESPONSES TO HUMAN TUMOUR ANTIGENS MADELINE HODKINSON* AND G. TAYLOR From the Immunology Department, Royal Infirmary, Manchester Received for publication May 14, 1969 THE most convincing

More information

Biological Consulting Services

Biological Consulting Services Biological Consulting Services of North Florida/ Inc. May 13, 2009 Aphex BioCleanse Systems, Inc. Dear Sirs, We have completed antimicrobial efficacy study on the supplied Multi-Purpose Solution. The testing

More information

CELLULAR KINETICS OF THE ANTI-MRBC RESPONSE IN CHICKENS

CELLULAR KINETICS OF THE ANTI-MRBC RESPONSE IN CHICKENS 19 CELLULAR KINETICS OF THE ANTI-MRBC RESPONSE IN CHICKENS K. Dagg, S. P. Turner and F. Seto Department of Zoology, University of Oklahoma, Norman, Oklahoma The serum hemagglutinin (HA) titers and the

More information

B16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small cell lung cancer

B16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small cell lung cancer Electronic Supplementary Material (ESI) for ChemComm. This journal is The Royal Society of Chemistry 2017 Experimental Methods Cell culture B16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small

More information

CELL-MEDIATED IMMUNITY TO ENCEPHALITOGENIC FACTOR (MMI TEST) IN WOMEN WITH CERVICAL DYSPLASIA AND CARCINOMA

CELL-MEDIATED IMMUNITY TO ENCEPHALITOGENIC FACTOR (MMI TEST) IN WOMEN WITH CERVICAL DYSPLASIA AND CARCINOMA Br. J. Cancer (1978) 38, 396 CELL-MEDIATED IMMUNITY TO ENCEPHALITOGENIC FACTOR (MMI TEST) IN WOMEN WITH CERVICAL DYSPLASIA AND CARCINOMA IN SITU: THE EFFECTS OF SERUM D. J. FLAVELL*l, A. SINGER2 AND C.

More information

ENHANCING EFFECT OF COENZYME Q10 ON IMMUNORESTORATION WITH MYCOBACTERIUM BOVIS BCG IN TUMOR-BEARING MICE*1

ENHANCING EFFECT OF COENZYME Q10 ON IMMUNORESTORATION WITH MYCOBACTERIUM BOVIS BCG IN TUMOR-BEARING MICE*1 ENHANCING EFFECT OF COENZYME Q10 ON IMMUNORESTORATION WITH MYCOBACTERIUM BOVIS BCG IN TUMOR-BEARING MICE*1 Ichiro KAWASE, Hisanobu NIITANI, Nagahiro SAIJO, Haruo SASAKI, and Tatsuhide MORITA National Cancer

More information

Macrophage-lymphocyte clustering in rheumatoid arthritis

Macrophage-lymphocyte clustering in rheumatoid arthritis Antn. rheum. Dis. (1975), 34, 38 Macrophage-lymphocyte clustering in rheumatoid arthritis F. W. S. WEBB, M. BAKER, R. WEISBART, R. BLUESTONE, AND L. GOLDBERG From the Department of Medicine, Rheumatology

More information

Comprehensive Cancer Cover

Comprehensive Cancer Cover Comprehensive Cancer Cover Tech Spec Comprehensive Cancer Cover provides the life insured with cover for the diagnosis and treatment of defined malignant tumours. These tumours must be characterised either

More information

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING

More information

Inhibition of Mwine CFU-C by Vindesine: Restoration of Colony Growth by Colony Stimulating Factor

Inhibition of Mwine CFU-C by Vindesine: Restoration of Colony Growth by Colony Stimulating Factor International Journal of Cell Cloning 1: 142-150 (1983) Inhibition of Mwine CFU-C by Vindesine: Restoration of Colony Growth by Colony Stimulating Factor Giuseppe Pigoli, Lina Mangoni, Cecilia CaFamatti,

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Chronic lymphocytic leukaemia 1 Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation

More information

Stimulation of Active K + Transport by Anti-L Antibodies in Trypsin-Treated Low Potassium Sheep Erythrocytes

Stimulation of Active K + Transport by Anti-L Antibodies in Trypsin-Treated Low Potassium Sheep Erythrocytes LETTER TO THE EDITOR Stimulation of Active K + Transport by Anti-L Antibodies in Trypsin-Treated Low Potassium Sheep Erythrocytes Dear Sir: In this letter we attempt to resolve a discrepancy on the effect

More information

Epidemiology in Texas 2006 Annual Report. Cancer

Epidemiology in Texas 2006 Annual Report. Cancer Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer

More information

Cellular Basis of Persistent Lymphocytosis in Cattle Infected

Cellular Basis of Persistent Lymphocytosis in Cattle Infected INFECTION AND IMMUNITY, June 1977, p. 891-897 Copyright 0 1977 American Society for Microbiology Vol., No. 3 Printed in U.S.A. Cellular Basis of Persistent Lymphocytosis in Cattle Infected with Bovine

More information

Studies of Peripheral Blood T- and B-Lymphocytes in Acute

Studies of Peripheral Blood T- and B-Lymphocytes in Acute INFEcTiON AND IMMUNITY, Jan. 1974, p. 1-7 Copyright i 1974 American Society for Microbiology Vol. 9, No. 1 Printed in U.S.A. Studies of Peripheral Blood T- and B-Lymphocytes in Acute Infections PER M.

More information

Calcium and Magnesium Contents of Mammalian Erythrocyte Membranes1) (Received July 3, 1972)

Calcium and Magnesium Contents of Mammalian Erythrocyte Membranes1) (Received July 3, 1972) No. 1 171 Chem. Pharm. Bull. 21(1)171-475(1973) UDC 591.05: 546.3.05.08 Calcium and Magnesium Contents of Mammalian Erythrocyte Membranes1) TATSUZO FUJII, TAKASHI SATO, and TAKASHI HANZAWA Faculty of Pharmacy,

More information

S2 File. Clinical Classifications Software (CCS). The CCS is a

S2 File. Clinical Classifications Software (CCS). The CCS is a S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous

More information

IN VITRO STUDIES OF INFLAMMATORY BOWEL DISEASE

IN VITRO STUDIES OF INFLAMMATORY BOWEL DISEASE GASTROENTEROLOGY 70: 171-176, 1976 Copyright 1976 b y The Willia ms & Wilkins Co. Vol. 70, No.2 Printed in U.S.A. IN VITRO STUDIES OF INFLAMMATORY BOWEL DISEASE Surface receptors of the mononuclear cell

More information

National Cancer Statistics in Korea, 2014

National Cancer Statistics in Korea, 2014 National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored

More information

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004 MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer

More information

vitro (4-9) impairment of immune responses may occur with Hodgkin's disease. This acquired immunodeficiency

vitro (4-9) impairment of immune responses may occur with Hodgkin's disease. This acquired immunodeficiency Hodgkin's Disease AN IMMUNODEPLETING AND IMMUNOSUPPRESSIVE DISORDER JEREMIAH J. TWoMEY, ARLINE H. LAUGHTER, SANDRA FARRow, and CGwuiRs C. DOUGLASS From the Department of Medicine, Baylor College of Medicine,

More information

PROPOSED USE This method is used for determining plasma reagins in human sera.

PROPOSED USE This method is used for determining plasma reagins in human sera. Agglutination Assay -glass slide For "in vitro" use only Store at 2-8 C INTRODUCRION Syphilis is a sexually transmitted disease caused by Treponema pallidum. The main tests used to diagnose syphilis are:

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

In Vitro and In Vivo Studies with Epstein-Barr

In Vitro and In Vivo Studies with Epstein-Barr A n n a l s o f C l i n i c a l L a b o r a t o r y S c i e n c e, Vol. 3, No. 6 Copyright 1973, Institute for Clinical Science In Vitro and In Vivo Studies with Epstein-Barr Virus (EBV)-------A Review

More information

Citation Acta Medica Nagasakiensia. 1992, 37

Citation Acta Medica Nagasakiensia. 1992, 37 NAOSITE: Nagasaki University's Ac Title Author(s) A Study on the Expression of EGFR a Content in the Stomach Cancer Tissu Nakazaki Takayuki Citation Acta Medica Nagasakiensia. 1992 37 Issue Date 1992-12-25

More information

chapter 8 CANCER Is cancer becoming more common? Yes and No.

chapter 8 CANCER Is cancer becoming more common? Yes and No. chapter 8 CANCER In Canada, about 4% of women and 45% of men will develop cancer at some time in their lives, and about 25% of the population will die from cancer. 1 Is cancer becoming more common? Yes

More information

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient? Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte

More information

Indium-111 Zevalin Imaging

Indium-111 Zevalin Imaging Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.

More information

Long-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up time

Long-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up time Original article Annals of Oncology 13: 1786 1791, 2002 DOI: 10.1093/annonc/mdf289 Long-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up

More information

Fractionation of Antigen Reactive Cells on a Cellular Immunoadsorbent: Factors Determining Recognition of Antigens by T-Lymphocytes

Fractionation of Antigen Reactive Cells on a Cellular Immunoadsorbent: Factors Determining Recognition of Antigens by T-Lymphocytes Proc. Nat. Acad. Sci. USA Vol. 69, No. 6, pp. 1620-1624, June 1972 Fractionation of Antigen Reactive Cells on a Cellular Immunoadsorbent: Factors Determining Recognition of Antigens by T-Lymphocytes (mouse

More information

Heterogeneity of 5 -Nucleotidase Activity in Lymphocytes in Chronic Lymphocytic Leukemia

Heterogeneity of 5 -Nucleotidase Activity in Lymphocytes in Chronic Lymphocytic Leukemia Heterogeneity of 5 -Nucleotidase Activity in Lymphocytes in Chronic Lymphocytic Leukemia John Lopes,, Dorothea Zucker-Franklin, Robert Silber J Clin Invest. 1973;52(5):1297-1300. https://doi.org/10.1172/jci107298.

More information

SOMAPLEX REVERSE PHASE PROTEIN MICROARRAY HUMAN KIDNEY TUMOR & NORMAL TISSUE

SOMAPLEX REVERSE PHASE PROTEIN MICROARRAY HUMAN KIDNEY TUMOR & NORMAL TISSUE SOMAPLEX REVERSE PHASE PROTEIN MICROARRAY HUMAN KIDNEY TUMOR & NORMAL TISSUE 45 CLINICAL CASES SERIAL DILUTION MULTIPLE PROTEIN CONCENTRATION QUANTITATIVE ASSAY PRODUCT NUMBER: PM1-001-N SOMAPLEX REVERSE

More information

Malignant Glial Neoplasms: Definition of a Humoral Host Response to Tumor-Associated Antigen(s)

Malignant Glial Neoplasms: Definition of a Humoral Host Response to Tumor-Associated Antigen(s) THE YALE JOURNAL OF BIOLOGY AND MEDICINE 50 (1977), 397-403 Malignant Glial Neoplasms: Definition of a Humoral Host Response to Tumor-Associated Antigen(s) KHALID M.A. SHEIKH, MICHAEL L.J. APUZZO, KIM

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

SUPPLEMENTARY INFORMATION. CXCR4 inhibitors could benefit to HER2 but not to Triple-Negative. breast cancer patients

SUPPLEMENTARY INFORMATION. CXCR4 inhibitors could benefit to HER2 but not to Triple-Negative. breast cancer patients SUPPLEMENTARY INFORMATION CXCR4 inhibitors could benefit to HER2 but not to Triple-Negative breast cancer patients Lefort S. 1,2, Thuleau A. 3, Kieffer Y. 1,2, Sirven P. 1,2, Bieche I. 4, Marangoni E.

More information

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of

More information

Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER

Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER Table 1.1 gives the total number of cancers diagnosed at five different hospital based cancer registries (HBCRs), over the period of two years from 1st January

More information

Secondary fluorescent staining of virus antigens by rheumatoid factor and fluorescein-conjugated anti-lgm

Secondary fluorescent staining of virus antigens by rheumatoid factor and fluorescein-conjugated anti-lgm Ann. rheum. Dis. (1973), 32, 53 Secondary fluorescent staining of virus antigens by rheumatoid factor and fluorescein-conjugated anti-lgm P. V. SHIRODARIA, K. B. FRASER, AND F. STANFORD From the Department

More information

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma Original article Annals of Oncology 13: 1908 1914, 2002 DOI: 10.1093/annonc/mdf333 Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma

More information

Production of Interferon Alpha by Dengue Virus-infected Human Monocytes

Production of Interferon Alpha by Dengue Virus-infected Human Monocytes J. gen. Virol. (1988), 69, 445-449. Printed in Great Britain 445 Key words: IFN-ct/dengue virus/monocytes Production of Interferon Alpha by Dengue Virus-infected Human Monocytes By ICHIRO KURANE AND FRANCIS

More information

PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES

PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES 71 PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES Harold G. Jensen, Alan J. Parkinson, and L. Vernon Scott* Department of Microbiology & Immunology, University of Oklahoma

More information

THE ANALYSIS OF MALIGNANCY BY CELL FUSION II. HYBRIDS BETWEEN EHRLICH CELLS AND NORMAL DIPLOID CELLS

THE ANALYSIS OF MALIGNANCY BY CELL FUSION II. HYBRIDS BETWEEN EHRLICH CELLS AND NORMAL DIPLOID CELLS J. Cell Sci. 8, 673-68 (97) 673 Printed in Great Britain THE ANALYSIS OF MALIGNANCY BY CELL FUSION II. HYBRIDS BETWEEN EHRLICH CELLS AND NORMAL DIPLOID CELLS U. BREGULA,* G. KLEIN Department of Tumor Biology,

More information

Improved Immunodiagnosis of Neutrophil Dysfunction in the Newborn and Infant

Improved Immunodiagnosis of Neutrophil Dysfunction in the Newborn and Infant ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 12, No. 2 Copyright 1982, Institute for Clinical Science, Inc. Improved Immunodiagnosis of Neutrophil Dysfunction in the Newborn and Infant ALAN B. LOREN,

More information

Biological Therapies for Cancer: Questions and Answers

Biological Therapies for Cancer: Questions and Answers Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments

More information

Comparison of Three Fat Graft Preparation Methods: Gravity Separation, Centrifugation, and the Cytori Puregraft System

Comparison of Three Fat Graft Preparation Methods: Gravity Separation, Centrifugation, and the Cytori Puregraft System PUREGRAFT Comparison of Three Fat Graft Preparation Methods: Gravity Separation, Centrifugation, and the Cytori Puregraft System John K. Fraser Ph.D., Min Zhu M.D., Douglas M. Arm Ph.D., Johnson C. Yu

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

Depleting Lipoproteins from Serum

Depleting Lipoproteins from Serum Depleting Lipoproteins from Serum Kathy K. Foxx Kalen Biomedical LLC President For decades, fetal bovine serum (FBS) has been used as a supplement for cell-culture media, providing the growth factors that

More information

NIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.

NIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17. NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups

More information

AGGLUTINATION PHENOMENA IN CANCER

AGGLUTINATION PHENOMENA IN CANCER AGGLUTINATION PHENOMENA IN CANCER N. WATERMAN AND L. DB KROMME (Laboratory of the Antoni van Leeuwenhoekhuie, Amsterdam) In the course of our investigations into the cytolysis of cancer cells by different

More information

Use of Trypsin-Modified Human Erythrocytes

Use of Trypsin-Modified Human Erythrocytes APPLIED MICROBIOLOGY, Sept. 1972, p. 353-357 Copyright i 1972 American Society for Microbiology Vol. 24, No. 3 Printed in U.S.A. Use of Trypsin-Modified Human Erythrocytes in Rubella Hemagglutination-Inhibition

More information

Clinical Policy: Donor Lymphocyte Infusion

Clinical Policy: Donor Lymphocyte Infusion Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte

More information

Virus Harvest AAV 15 cm 2

Virus Harvest AAV 15 cm 2 Virus Harvest AAV 15 cm 2 1) Gently scrape cells from plate in 10 ml of media, place remaining 10 ml of media in plate lid. 2) Once cells are removed from plate, wash plate by pipetting 20 ml of media

More information

Understanding the role of ex vivo T cell depletion

Understanding the role of ex vivo T cell depletion Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This

More information

McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells

McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells Effects of McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells X.C. Wei, D.D. Yang, X.R. Han, Y.A. Zhao, Y.C. Li, L.J. Zhang and J.J. Wang Institute of hematological research,

More information

Cancer Risk Factors in Ontario. Other Radiation

Cancer Risk Factors in Ontario. Other Radiation Cancer Risk Factors in Ontario Other Radiation OTHer radiation risk factor/ exposure Radon-222 and decay products X-radiation, gamma radiation Cancer The context where high risks were reported Magnitude

More information

Analysis of the Viability of Umbilical Cord blood Stem Cells. Sachdeva N

Analysis of the Viability of Umbilical Cord blood Stem Cells. Sachdeva N Jsrm/Vol5No.11, 2009 Original Article Analysis of the of Umbilical Cord blood Stem Cells Sachdeva N Dr. Neelam Sachdeva Reader, Department of Zoology, Gargi College, University of Delhi, Siri Fort Road,

More information

Syphilis. syphilis. Sera from all stages of syphilis and the. to compare dilution titers with those obtained

Syphilis. syphilis. Sera from all stages of syphilis and the. to compare dilution titers with those obtained JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1982, p. 238-242 0095-1137/82/020238-05$02.00/0 Vol. 15, No. 2 Unheated Serum Reagin Test as a Quantitative Test for Syphilis DEBORAH E. PETTIT, SANDRA A. LARSEN,*

More information

Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5).

Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5). Appendix Definitions of Index Admission and Readmission Definitions of index admission and readmission follow CMS hospital-wide all-cause unplanned readmission (HWR) measure as far as data are available.

More information

Personalized medicine - cancer immunotherapy

Personalized medicine - cancer immunotherapy Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital

More information

EBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham

EBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Infection and Immunity Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Introduction Large ds DNA virus Spread by saliva contact Lifelong infection Predominantly B-lymphotropic

More information

Gladstone Institutes, University of California (UCSF), San Francisco, USA

Gladstone Institutes, University of California (UCSF), San Francisco, USA Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24 Gag Marianne Gesner, Mekhala Maiti, Robert Grant and Marielle Cavrois * Gladstone Institutes, University of

More information

Validation of the Efficacy of a Practical Method for Neutrophils Isolation from Peripheral Blood

Validation of the Efficacy of a Practical Method for Neutrophils Isolation from Peripheral Blood Validation of the Efficacy of a Practical Method for Neutrophils Isolation from Peripheral Blood JONATHAN DEGEL, MASIH SHOKRANI OBJECTIVE: The objectives of this study were to validate the Polymorphprep

More information

Immunoperoxidase detection of T and B cells in blood compared with conventional methods

Immunoperoxidase detection of T and B cells in blood compared with conventional methods J Clin Pathol 1984;37:1343-1347 Immunoperoxidase detection of T and B cells in blood compared with conventional methods PK HUI*, JWM LAWTONt From the *Haematology and timmunology Units, Department ofpathology,

More information

Bioengineering and World Health. Lecture Twelve

Bioengineering and World Health. Lecture Twelve Bioengineering and World Health Lecture Twelve Four Questions What are the major health problems worldwide? Who pays to solve problems in health care? How can technology solve health care problems? How

More information

Key words: Collagen synthesis - N-Terminal peptide of type III procollagen - Tumor marker - Liver cancer - Liver cirrhosis

Key words: Collagen synthesis - N-Terminal peptide of type III procollagen - Tumor marker - Liver cancer - Liver cirrhosis [Gann, 75, 130-135; February, 1984] HIGH CONCENTRATIONS OF N-TERMINAL PEPTIDE OF TYPE III PROCOLLAGEN IN THE SERA OF PATIENTS WITH VARIOUS CANCERS, WITH SPECIAL REFERENCE TO LIVER CANCER Terumasa HATAHARA,

More information

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant

More information

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected

More information

16 Effect of cell surface N-linked oligosaccharide chains on the compaction of preimplantation mouse embryos

16 Effect of cell surface N-linked oligosaccharide chains on the compaction of preimplantation mouse embryos 16 Effect of cell surface N-linked oligosaccharide chains on the compaction of preimplantation mouse embryos H.Hayashi, N.Minami, M.Yamada and K.Utsumi Department of Animal science, College of Agriculture,

More information

Chemotherapy-Induced Immunosuppression

Chemotherapy-Induced Immunosuppression Environmental Health Perspectives Vol. 43, pp. 21-25, 1982 Chemotherapy-Induced Immunosuppression by Lucy Rasmussen* and Ann Arvin* Chemotherapeutic agents are used widely in clinical medicine for the

More information

July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American

More information

ALETA : MODE OF ACTION

ALETA : MODE OF ACTION ALETA : MODE OF ACTION Lakshmibai Vasanthakumari Bindhu. PhD ABSTRACT Previous research has shown that beta-glucan has immunomodulatory effects. Paramylon is the beta-glucan found in Aleta and forms granules.

More information

Rubella Latex Agglutination Test

Rubella Latex Agglutination Test Rubella Latex Agglutination Test Cat. No.:DLAT1088 Pkg.Size:30T Intended use The Rubella Latex Agglutination Test is a rapid latex particle agglutination test for the qualitative and semi-quantitative

More information

CANCER FACTS & FIGURES For African Americans

CANCER FACTS & FIGURES For African Americans CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5

More information

Tumor responses (patients responding/ patients treated)

Tumor responses (patients responding/ patients treated) Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing

More information

Introduction.-Cytopathogenic viruses may lose their cell-destroying capacity

Introduction.-Cytopathogenic viruses may lose their cell-destroying capacity AN INHIBITOR OF VIRAL ACTIVITY APPEARING IN INFECTED CELL CULTURES* BY MONTO Hot AND JOHN F. ENDERS RESEARCH DIVISION OF INFECTIOUS DISEASES, THE CHILDREN'S MEDICAL CENTER, AND THE DEPARTMENT OF BACTERIOLOGY

More information

Adoptive Transfer of Immunity to Plasmodium berghei with Immune T and B Lymphocytes'

Adoptive Transfer of Immunity to Plasmodium berghei with Immune T and B Lymphocytes' INMCTION AND ImmuNrry, July 1976, p. 184-190 Copyright 1976 American Society for Microbiology Vol. 14, No. 1 Printed in U.S.A. Adoptive Transfer of Immunity to Plasmodium berghei with Immune T and B Lymphocytes'

More information

Tumor Immunology. Tumor (latin) = swelling

Tumor Immunology. Tumor (latin) = swelling Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to

More information

Aplastic anemia. Case report. Effect of antithymocyte globulin on erythroid colony formation

Aplastic anemia. Case report. Effect of antithymocyte globulin on erythroid colony formation Case report Aplastic anemia Effect of antithymocyte globulin on erythroid colony formation Susan A. Rothmann Hamburger, Ph.D. Department of Laboratory Hematology and Blood Banking James H. Finke, Ph.D.

More information

I cipal factor determining the prognosis of

I cipal factor determining the prognosis of CORRELATES OF SURVIVAL AFTER INITIATION OF CHEMOTHERAPY IN 142 CASES OF HODGKIN S DISEASE ALAN RAPOPORT, MD,* PHILIP COLE, MD, MPH,~ AND JOHN MASON, MD~ A series of 142 patients with Hodgkin s disease

More information